Literature DB >> 874961

Preparation and antitumor activity of 1-aryl-3,3-dimethyltriazene derivatives.

T Giraldi, C Nisi, T A Connors, P M Goddard.   

Abstract

Several 1-aryl-3,3-dimethyltriazene derivatives have been synthesized and tested for their antitumor activity against the TLX5 lymphoma in mice. These compounds are characterized by the presence of a carbonyl group bound to the benzene nucleus in the para position to the triazene funciton. Three p-sulfamoyl derivatives have also been included and proved to be inactive. Among the carbonyl derivatives compounds 1 and 20, which can be used as reference, cause ILS of about 50%, respectively, at four and three dose levels. Compound 16, the o-nitro-phenylhydrazone of the hydrazide 1, is active at all six dose levels studied. The adduct 19, obtained from the same hydrazide and p-nitrobenzaldehyde, is active at four dose levels, and the ILS values at two optimum doses are significantly greater than those caused by compound 1.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 874961     DOI: 10.1021/jm00216a025

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Synthesis and biological evaluation of glycosides containing triazene-chalcones.

Authors:  Qiang Lei; Saiyang Zhang; Manli Liu; Jia Li; Xi Zhang; Yue Long
Journal:  Mol Divers       Date:  2017-08-08       Impact factor: 2.943

2.  Effects of an inducer and an inhibitor of hepatic metabolism on the antitumor action of dimethyltriazenes.

Authors:  G Sava; S Zorzet; L Perissin; T Giraldi; L Lassiani
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Antitumor effects of GANU and other nitrosourea derivatives against transplantable leukemias and solid tumors in mice.

Authors:  G Sava; T Giraldi
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.

Authors:  B J Foster; D R Newell; J Carmichael; A L Harris; L A Gumbrell; M Jones; P M Goodard; A H Calvert
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.